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ABSTRACT OF THE THESIS
HYDRODYNAMIC ASSESSMENT OF A PORCINE SMALL INTESTINAL SUBMUCOSA BIOSCAFFOLD VALVE FOR PEDIATRIC MITRAL VALVE
REPLACEMENT
by
Omkar Mankame
Florida International University, 2017
Miami, Florida
Professor Sharan Ramaswamy, Major Professor
Valve replacement for critical heart valve diseases is in many cases not an option. Our
clinical experience in pediatric compassionate care has shown robust function of porcine
small intestinal submucosa (PSIS) valves. We assessed functional effectiveness of 4ply
(~320µm) and 2ply (~166µm) PSIS mitral valves under pediatric-relevant hemodynamic
pulsatile conditions. Key conclusions: (i)PSIS valves demonstrated statistically similar
acute functionality in comparison to a commercially available valve. (ii)Energy losses were
similar (p>0.05) under pediatric conditions which was not the case under adult aortic
conditions. (iii)2ply valves were observed to be superior to 4ply, based on the robust
hydrodynamic data, the mechanical properties suitable for pediatric applications and denovo tissue replacement potential with less demand on the body. Demonstrating somatic
growth, valve tissue filling matching PSIS degradation and PSIS-valve fatigue assessment
are critical endeavors that need to be carried out to ensure mid to long term function of
these bioscaffold mitral valves.
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CHAPTER 1 Introduction
Heart valves perform a very important role in regulating the forward flow of blood
initiating from the four chambers of the heart (Fig. 1). Heart valves help in coordinating
blood flow during the cardiac cycle. They have a direct effect on the overall efficiency of
the cardiovascular system. Tissue leaflets in the valves open and close with each beat of
the heart and in healthy states, permit robust hemodynamic conditions. Critical heart valve
disease, a serious health issue, often requires valve replacement with a prosthetic valve. In
the young, critical congenital valve anomalies have been a life-threatening condition and
has frequently resulted in mortality [1]. In the United States, there are an estimated 650,000
to 1.3 million children and adults living with congenital heart disease [2]. A common
cardiac abnormality occurs with the cardiac valves, which accounts for 30% of all
congenital heart problems [3].

Figure 1: (a) Anatomy of heart valves (Ho S. Y, 2002). (b) The mitral apparatus:
Continuity of the mitral apparatus and the left ventricular myocardium (Otto C.M, 2001).
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Heart valves open and close due to the pressure difference between either side of the
valve. Heart valve disease occurs if one or more of the valves function abnormally. The
complications that can develop with these valves are mainly of two types: (a) stenosis and
(b) regurgitation and prolapse [4, 5, 6]. Stenosis occurs when there is obstruction to the
flow of blood in the forward direction. This may occur if the valves do not open fully or
narrowing of the orifice area of the valve [7]. Alternatively, there may a narrowing of the
vessel (e.g. aorta) at the site of the valve due to congenital causes. Stenosis can result in
increased work load on the heart as the heart needs to pump harder to drive the blood
through the stenosed region [8]. On the other hand, if the valve is diseased, such that it does
not close completely or form a tight seal between leaflets, then there will be leakage that
will cause the back-flow of blood [9]. This defect is called regurgitation. Regurgitation also
puts an extra strain on the heart to pump the necessary volume of blood in the right
direction. Congenital defects include atresia, which occurs if the heart valves are not
formed properly or are partially or fully absent, causing loss of sufficient local control to
permit unidirectional blood flow. All four valves can be prone to congenital problems
and/or disease, but the aortic and mitral valves which are commonly affected [10] can lead
to death very quickly owing to high hemodynamic blood pressures on the left side of the
heart.
Depending on the severity of the diseased heart valve condition, the valve is either
treated with vasodilators, repaired or is replaced completely [11]. For mild valvular disease,
clinicians may prescribe vasodilators or diuretics to assist in promoting enhanced blood
flow. However, if the valves are severely damaged, valve repair/replacement surgeries are
usually recommended [11]. Some of the valve repair procedures that a surgeon can perform
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are decalcification, patching, balloon valvuloplasty, reshaping and leaflet extension
techniques. Valve replacement surgeries are typically performed when the valves are
beyond repair. Aortic and mitral valve replacement surgeries are common-place today with
reasonably good outcomes. However, some segments of the population are not suitable
candidates for valve replacement either because valve sizing/growth issues exist (e.g. in
pediatric patients) or because of complications that can occur with the surgery and/or
specific prosthetic being used (e.g. women who wish to have children cannot have a
mechanical valve since it requires lifelong anticoagulant therapy).
Heart valves are surgically replaced when they fail to operate physiologically. Heart
valve prostheses, like mechanical valves (caged ball, tilting disc, hinged bileaflet) which
are made of artificial materials, chemically fixed animal tissue bioprosthetic valves
(porcine or bovine tissue) and homografts (human cadaver valves) are generally used for
valve replacement surgeries. Mechanical valves are very strong and durable and are
functional for longer durations, in some patients they have lasted as long as 25 years
without problems [12]. However, as previously mentioned, these valves constantly require
continuous use of anticoagulants since the mechanical valves is prone to thrombus
formation. Glutaraldehyde-fixed bioprosthetic valves or tissue valves have shorter lifespan as compared to the mechanical valves, generally a mean life-span of 10 years, but on
the other hand, these valves do not require anticoagulant treatment. Bioprosthetic valves
are similar to native human valves and also have better hemodynamic characteristics than
mechanical valves. Bioprosthetic valves are also a preferred candidate among the elderly
(> 65 years of age) as it can also be implanted in a minimally invasive manner (e.g.
transcatheter aortic valve replacement/TAVR). Typically, current available prostheses can
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be utilized in adults, but for replacement procedures in infants and young patients they are
not suitable.
Utilization of currently available tissue and mechanical prosthetic valve substitutes in
infants and children have restrictions in terms of the relatively large size of available
prosthetic devices, somatic growth, durability, thrombogenicity and endocarditis or
susceptibility to infection. All the mechanical valves involve permanent use of
anticoagulation. This may present greater risk to infants and children who are prone to
accidental injury during play [13]. Bioprosthetic valves degrade quickly in young patients
and are prone to accelerated calcification. However, above all, sizing limitations and an
inability to support valvular growth are the two major drawbacks of prosthetic heart valves.
Over the past few years, better surgical approaches have aided children, suffering with
congenital heart defects, to survive into adulthood [14]. Regardless of these developments,
significant number of patients require multiple operations [14]. Of late it has been shown
that after implantation, acellular porcine small intestinal submucosa (PSIS) scaffolds have
potential capacity to support hemodynamic functions and permit PSIS bioscaffold
replacement by organized collagen and colonization of cells similar to the endothelial cells
[15, 16].
PSIS is a biodegradable, naturally occurring scaffold material which degrades with
time promoting in vivo tissue growth. These scaffolds support cell infiltration and tissue
remodeling after implantation. Cardiovascular use of PSIS patches in vivo in animal models
has been promising demonstrating restoration and integration [17, 18, 19]. PSIS valves
have the potential to address the complications posed by conventional heart valve
substitutes and thus, offer a possibility that they may be used as a permanent approach for
4

replacing defective heart valves, since somatic growth can in theory, be facilitated. Our
collaborators at Joe DiMaggio Children’s Hospital (Hollywood, FL) have implanted
custom-made PSIS valves in 4 infants with critical valve disease unable to receive standard
valves, as compassionate care measures. The follow-ups (post-1 year) have been promising
and have reported that the valves have performed well, with low transvalvular pressure
gradients and no need for anti-coagulant therapy [15]. These are remarkable observations
given that these patients would have died within a few days to weeks if left untreated and
also again in recognizing that no current treatment option exists for these patients; if
successful PSIS valves may offer the potential to revolutionize the treatment of critical
congenital valve diseases.
Although PSIS material possesses desirable cardiovascular traits, before this
technology can be used on a wider scale for valve applications, an organized evaluation of
PSIS valves functionality is needed so that any long-term complications beyond a few years
post-implant can be identified. It is important to recall that the valve needs to function and
grow for 18 years till adulthood. One way in which functionality can be evaluated is
through hydrodynamic assessment with a pulse duplicator (Vivitro System, Vivitro
Laboratories, Victoria, Canada).
Previously we evaluated PSIS prosthetic bioscaffold valves in the aortic position in
vitro by utilizing a pulse duplicator system (Vivitro Laboratories, Victoria, Canada) [20].
We analyzed the hydrodynamic functionality of PSIS trileaflet bio scaffold valves
(CorMatrix Cardiovascular, Inc., Roswell, GA, USA) by comparing these valves with
bioprosthetic valves (Medtronic Freestyle, Medtronic, Minneapolis, MN) under
physiological adult conditions at a heart rate of 70 bpm and stroke volume of 80 ml/beat.
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Here we chose Medtronic bioprosthetic valves as a control. Hydrodynamic testing results
exhibited robust functionality of the PSIS valves and the valves preformed very close to
the commercially available Medtronic freestyle bio-prosthetic valve [20]. However, the
PSIS aortic valves exhibited a cause of concern in that significantly higher (p < 0.05)
energy losses were observed, which could lead to longer term complications due to
increased workload on the heart.
The focus of this thesis was to evaluate the acute functionality of mitral 4ply PSIS
valves (~ 320µm) under varying pediatric physiological conditions and compare the results
with those of commercially available bioprosthetic valves (Edwards Lifesciences, Irvine,
CA). The series of experiments were performed to determine the effects of varying
physiologically-relevant pediatric heart rates and stroke volumes on in vitro hydrodynamic
functionality of manually-assembled PSIS mitral valves. Subsequently we moved on to the
thinner 2ply valves (~ 166µm) in order to test if the thinner PSIS valve maintained its
hydrodynamic functionality. The end-goal of this work was to identify hydrodynamic
metrics of PSIS bioscaffold mitral valves under pediatric conditions and thus contribute
towards the optimization of these constructs for the potential treatment of critical valvular
diseases.
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CHAPTER 2 Specific Aims
Currently there are no valve replacement strategies that can completely replace the
defective human mitral valve, having the ability to grow with the patient. Commercially
available prosthetic valves also have other shortcomings in terms of durability,
thrombogenicity and endocarditis. This problem is more evident in infants and small
children, as they grow with time but prosthetic valves remain the same size, thus requiring
multiple reoperations. Tissue engineered heart valve (TEHV) development has the
capability to offer growth, resistance to infection, self-repair and a permanent attempt for
substituting diseased and defective heart valves and treat critical congenital valve disease
in pediatric patients, which the current valve substitutes lack [1]. Nevertheless, a major
challenge in this concept is to discover a scaffold which is biocompatible with in vivo
hemodynamic conditions and biodegradable, which can provide for somatic growth in the
longer term.
In 2015, the Food and Drug Administration (FDA) approved valve replacement
procedures of trileaflet PSIS valves (Cormatrix: April 2015) in up to 15 patients. The
overall purpose of this work was to propose a simple and novel approach for the treatment
of critical pediatric congenital heart valve disease by using an extracellular porcine small
intestinal submucosa (PSIS) bioscaffold construct for valvular replacement. Our
collaboration with our clinical colleagues at Joe DiMaggio Children’s Hospital
(Hollywood, FL) has shown promising results with PSIS scaffolds working flawlessly in
pediatric compassionate care patients, the longest follow up being around 2 years. PSIS
has exhibited the ability to recruit endogenous cardiovascular cells, leading to
phenotypically-matched tissue replacement when the scaffold degrades completely [2,3].
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This property to permit implantation of the scaffold without in vitro cell seeding and
culturing is attractive specially for pediatric valvular applications and has a huge potential,
where somatic growth is crucial. However, there are mixed clinical reports regarding PSIS
bioscaffold with the key apprehensions being enduring inflammatory response and the
absence of a tri-layered valve structure after some months of implantation [4, 5].
Nevertheless, no large-scale, organized valvular study to evaluate PSIS valve capability
has been performed till date.
The immediate objective of this study was to assess in vitro hydrodynamic functionality
of PSIS bioscaffolds in mitral valve replacement application, especially for infants and
small children. Our work combined assessing the hydrodynamic functionality of PSIS
bioscaffold valve in an in-house pulse duplicator system (Vivitro Laboratories, Victoria,
BC) under varying native pediatric conditions (aim 1) and then optimizing the PSIS
bioscaffold dimensions to the best selected pediatric environment in the same simulator
(aim 2) in order to establish the in vitro functionality of PSIS-valve as a strategy for the
treatment of pediatric, critical congenital valve diseases. Our two specific aims are as
follows:
Specific Aim 1: Identifying the biofluid dynamics of novel 4ply PSIS bileaflet
valves (~320µm) for functional assessment in the mitral position at varying pediatric
conditions. By biofluid dynamics we aim to establish certain fluid mechanical
parameters that will aid us towards understanding if the valves function
appropriately. These include but are not limited to pressure gradient across the valve,
forward flow, effective orifice area, regurgitation fraction and the systolic energy
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losses. Insights into these parameters for PSIS valves will provide both acute as well
as prediction on mid to long term performance.
We accomplished this by using a left heart simulator in our laboratory [6, 7]. This
study was conducted by suturing a bi-leaflet valve configuration in the mitral position in
the pulse duplicator system (Vivitro Laboratories, Victoria, BC) and exposing the valves
to pediatric native mitral valve hemodynamic conditions in order to predict potential longterm complications. Pediatric conditions had two sets of testing parameters; one at constant
heart rate and other at constant stroke volume. Our current experience with PSIS
bioscaffolds is based on constructs measuring 320 µm in mean thickness (n = 5 leaflets)
and a leaflet radius of  8mm, using lobe-shaped leaflets. The leaflet width was scaled to
fit into the vascular conduit into which the valve is sutured.
Specific Aim 2: Establish the feasibility of 2ply PSIS mitral valves (~166µm) with
~47% reduction in thickness and ~54% reduction in volume as compared to the 4ply
valves (~320µm) in aim 1. The underlying goal of this aim is to reduce the burden on
the body to produce de novo tissues since less biomaterial will be used.
Owing to the unique material properties of PSIS, our hypothesis is that PSIS
bioscaffold valvular dimensions can be further minimized, ideally by 50% of current
bioscaffold thickness, while still allowing for robust functionality, and in addition, will
support de novo valvular tissue formation and somatic growth in vivo From the
hydrodynamic metrics measured, the leaflet thickness was fine-tuned through an iterative
process to establish robust functionality for the mitral position with PSIS bioscaffold
material. Thus, when implanted, this in turn will reduce the burden on the host since less
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tissue is required to fill a smaller scaffold space. These valves were subjected to the best
selected pediatric condition from aim 1 within the same pulse duplicator system.
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CHAPTER 3 Literature Review
3.1. Anatomy and Physiology of Heart Valves:
The mitral valve is located on the left side of the heart connecting the left atrium and
the left ventricle [1, 2]. On the contrary, tricuspid valve is located between the right atrium
and right ventricular chambers. Together these valves are referred to as “atrioventricular
valves”. The mitral valve has two leaflets unlike the other cardiac valves while the tricuspid
valve has three cusps [2]. Similarly, there are two “semilunar valves” namely aortic and
pulmonary valves and are correspondingly positioned in the left and right ventricular tract.
Both these valves are tri-leaflet valves consisting of three semilunar cusps. The mitral and
the aortic valves are structured close to each other whereas the pulmonary and the tricuspid
valves are separated by myocardium. Of specific interest to this study is the mitral valve.
The mitral valve leaflets control the flow of blood at the orifice between the left atrium
(LA) and the left ventricle (LV) and open during diastole to allow the blood flow from the
LA to the LV. During ventricular systole, the left ventricle muscle contracts causing the
mitral valve leaflets to close and prevents back flow to the LA. Blood is ejected through
the open aortic valve. The mitral valve is a complex structure that depends on its 6
components, which are the left atrial wall, the annulus, the leaflets, the chordae tendineae,
the papillary muscles, and the left ventricular wall [3, 4]. Any congenital or acquired
disorder as a result of rheumatic fever or degenerative change of individual components
can disturb the synchronized mechanisms of the mitral valve and result in a malfunctioning
heart valve [3, 5, 6].
A single heart beat comprises of a cardiac cycle which can be thought to initiate with
blood ejection from the left ventricle to the systemic circulation and is completed when the
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heart is filled again with blood. There are two sub-phases in a single cardiac cycle; systole
and diastole. During the diastolic phase, the ventricles are relaxed and the atria contract.
This leads to the opening of mitral and tricuspid valves. On the contrary, aortic and
pulmonary valves are closed during the diastolic phase. The opening of the atrioventricular
valves allows the flow of blood from the atria to the ventricles (Fig. 2) and the closing of
the semilunar valves prevents back flow of blood into the atria. During the systolic phase,
the ventricles are contracted as the impulse from SA node spreads to the ventricles. This
contraction opens the semilunar valves to allow ejection of blood into the arteries. At the
same time, mitral and tricuspid valves snap shut, blocking the flow of blood into left and
right ventricles. However, blood continues to enter the atria though the vena cavae and
pulmonary veins. Each cardiac cycle is crucial for the proper functioning of the
cardiovascular system.

Figure 2: The heart in diastole (during relaxation of the left ventricle). In normal
individuals, the heart valve opens to allow blood to flow into the left ventricle; notice the
supporting structure of tendon and muscle (Turi A, 2004).
14

3.2. Mitral Valve Disease:
The mitral valve is the most complex amongst the four valves of the heart and is the
most commonly associated with disease [7]. Mitral valve disease can be acquired due to
rheumatic fever, infections or due to ageing or this disease may occur before birth as the
heart is developing. Congenital mitral valve abnormalities are either observed in seclusion
or with other congenital heart disease. There are 3 different types of irregularities related
to the mitral valve: mitral stenosis, mitral regurgitation, mitral prolapse (Fig. 3).

Figure 3: (a) Extensive calcification of the mitral annulus (Cherry A.D, 2016). (b) In the
patient with both prolapse and mitral regurgitation, the valve does not close completely
and part of a leaflet bulges back into the left atrium (Turi A, 2004).
3.2.A. Mitral Stenosis:
Mitral stenosis prevents the proper opening of the valves during diastolic phase thus
filling the ventricles with inadequate blood volume. It is a structural malformation of the
mitral valve which results in hardening of the leaflets which prevents leaflet movement,
thus obstructing cleft ventricular inflow. Rheumatic carditis is the main cause of mitral
stenosis. Rheumatic carditis and mitral stenosis are interrelated as stenosis of mitral valves
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occurs in 40% of all patients with rheumatic heart disease [8]. Congenital mitral stenosis
was noted to affect multiple mitral valve segments as observed by Ruckman and van
Praagh in 1978 [9].
3.2.B. Mitral Regurgitation
Mitral regurgitation is divided into either primary (a structural or degenerative
abnormality of the mitral valve apparatus) or secondary (a disease of the left ventricle,
which interferes with the function and integrity of the mitral valve apparatus) mitral
regurgitation [10]. This anomaly leads to backflow or leakage of blood from the left
ventricular chamber to the left atrium through the mitral valve. During systole, the mitral
valve suffering from regurgitation irregularity does not close properly and hence the
contracting ventricles push blood back into the left atrium. Severe regurgitation increases
the workload on the heart to maintain the forward flow and thus can lead to malfunction of
the heart. Hemodynamically regurgitation is most common anomaly related to mitral valve
as compared to mitral stenosis [9]
3.2.C. Mitral Prolapse
Bulging of mitral valves back into the left atrium is called as mitral valve prolapse. In
mitral valve prolapse, during contraction of the left ventricle (systole), one or both the
leaflets prolapse into the left atrium causing the leakage of blood back into the atrium
through the open orifice area. The valve usually becomes floppy and does not close the
valve tightly. This abnormality usually leads to palpitations, shortness of breath, pain in
chest. Severe mitral prolapse raises the pressure in the left atrium to adjust the forward flow
and thus can cause heart failure. Mild prolapse can be treated with medications which helps
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to avert complications. Some people, however, need mitral valve repair or valve
replacement surgeries if the problem is too severe.
Generally, for mitral stenosis, a balloon valvotomy procedure is usually prescribed. It
is a minimally invasive procedure in which a catheter tube is inserted through an artery in
the arm or groin and upon reaching the mitral valve location, the balloon at the tip of the
catheter is inflated swiftly. This helps in separating the narrowed valves and ultimately
increases the forward flow of blood. Other valvotomy techniques have also been developed
for mitral valve regurgitation. Valve repair techniques provide better morbidity, mortality
and long-term outcomes as compared to the valve replacement procedures [11]. On the
contrary, valve replacement is must for severe valve damage where valve repair is not an
option.
The European Association of Echocardiography and the American Society of
Echocardiography Recommendations for Clinical Practice has defined the criteria for
severity of mitral regurgitation and stenosis based on hemodynamics (Table 1).
Table 1: Severity of mitral valve stenosis based on hemodynamics.
Mitral
Valve
Mild
Moderate
Severe

Regurgitation Fraction (%) [12]
< 30
30-49
≥ 50

Mean transvalvular pressure gradient
(diastole) (mmHg)* [13]
<5
5-10
>10

* At heart rates between 60 and 80 bpm.
3.3 Prosthetic Heart Valves:
Heart valve replacement surgery was introduced in the early 1960s which improved the
outcome of patients with valve related abnormalities [14]. Original Starr-Edwards
prosthesis were used in 1960s and the few of the patients who underwent valve replacement
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surgeries with these valves are reported to be alive [11]. As explained by a pioneer cardiac
surgeon, Dr. Dwight Harken, a model prosthetic valve to be used in humans should have
outstanding hemodynamic properties, high resistance to thrombosis, long-term durability
and also excellent implantability [15]. These valves should work excellently in
coordination with the entire circulatory system. It should imitate the characteristics of a
normal human native valve.
3.3.A. Mechanical Valves:
Mechanical valves are made of robust materials, primarily of metal or carbon alloy,
and are most durable valves among the replacement valves, most lasting at least 20 to 30
years [16]. However mechanical valves are thrombogenic in nature causing the blood to
clot and thus involve long-term anticoagulant therapy to prevent valve associated
thrombosis [17]. The blood clots can break off from one site and travel through the blood
stream (embolism) where they may lodge in blood vessels and cause further heart related
complications. Life-long warfarin therapy is necessary for the patients with mechanical
valve prosthesis [8]. It helps to avoid blood to clot, as the mechanical valves promote
clotting of blood which gets lodged in the flaps or hinges of the valves and thus cause
malfunction. Mitral valve replacement by mechanical prostheses is associated with higher
degrees of thromboembolism as compared to replacement in other valves [8, 16].
There are three types of mechanical valve designs that have been used in medical
practice (Fig. 4): caged ball valves, monoleaflet or disc valves and bileaflet valves. These
valves are described according to the shape of the occluder, that opens and closes the orifice
area of the valve. The caged ball mechanical valves, the original Star-Edwards 6120 and
1260 models, were developed as mitral and aortic valves respectively. These valves
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included a silastic ball with a circular sewing ring and a cage made of 3 metal curvatures
[11, 14]. The ball moves forward into the cage when open and seats back when closed. The
Starr-Edwards prosthesis has the longest implant history and durability of around 40 years.
However, these valves when implanted in patients reported very high thrombogenesis [16].
The patients needed very intensive anticoagulant therapy more than that required in any
other mechanical valves. The caged ball mechanical valves are no longer utilized for valve
replacement procedures as they are hemodynamically inferior to their more recent
counterparts.

Figure 4. (a) St Jude bileaflet mechanical valve. (b) Medtronic Hall monoleaflet
mechanical valve. (c) Starr-Edwards caged ball valve (Pibarot P, 2009).
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A monoleaflet valve has a single circular graphite disc, hence the name disc valve. The
disc leaflet is fixed by a lateral or central metal strut that tilts to open and closes to block
the valve orifice area. When the disc tilts open, it results in two different orifice areas of
different sizes. The opening angle of this singular disc in relation to the valve annulus
ranges from 60° to 80°. Karl-Victor Hall, Arne Wolen and Robert Kaster developed a
Hall-Medtronic single tilting-disc valves that was approved by US Food and Drug
administration in 1977 [15]. This valve is one of the valves with the longest implant history.
Hall-Medtronic valve prosthesis was later purchased by Medtronic, Inc.
St Jude bileaflet valve is also a type of mechanical valve which was approved by FDA
and introduced in 1977 [15]. Bileaflet valves have two semicircular leaflets or discs
connected by hinges to a stiff metal valve ring. During the forward flow of blood, both the
leaflets tilt open forming three orifices, two larger orifices on outer regions of the two
leaflets and one small orifice between these leaflets. Both the leaflets close when the
forward flow stops, thus obstructing the backflow of blood. These valves have the lowest
possibility of thromboembolism and thus require less use of anticoagulant agents [11]. Tilt
disc valves and bileaflet valves have similar properties.
3.3.B. Bioprosthetic Valves:
Bioprosthetic heart valves (Fig. 5) or biological valves are the tissue valves that are
constructed from animal tissues. Generally, low intensity anticoagulant therapy with
warfarin is suggested during the first 3 months after the bioprosthetic valves are implanted
[8, 16]. This is necessary as there is a risk of thromboembolism during the 3 months’ time
span. Nonetheless, compared to the mechanical valves, the bioprosthetic valves do not
require long-term anticoagulant therapy. Bioprosthetic valves are fixed in glutaraldehyde
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causing the crosslinking of collagen. This process masks the antigens and helps in chemical
stabilization leading to lower the immunogenicity (immune response of the body).
Bioprosthetic valves generally provide hemodynamic properties which are more similar to
those of the native valves. These valves are less durable and can normally last for around
10-15 years.

Figure 5: (a) Carpentier-Edwards Perimount Bovine Pericardial Tissue Valve. (b)
Carpentier-Edwards S.A.V. Porcine Stented Valve. (c) Edwards Prima Plus Porcine
Stentless Valve (Edwards Lifesciences®).
Autologous valves are constructed from the patient’s own tissue derived from deep
fascia, layer of dense connective tissue, of the thigh or pericardium. During 1970s valves
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were shaped by hand from patient’s own tissue during surgery [11]. However, these valves
have been abandoned as they were technically challenging and had limited durability.
Carpentier-Edwards Perimount pericardial prosthesis is an example of frame mounted
valves created from the patient’s own pericardium using a commercially available kit
which has been developed lately.
Bioprosthetic valves obtained from human tissue valves are of two types: autografts
and homografts. Autograft biological tissue valve replacement procedures generally
involve acquiring patient’s own valve from one site and implanting at the site where the
disease transpires. Usually this procedure is aimed at aortic valve defects, as described by
Donald Ross in 1967, where pulmonary valve is grafted at aortic site and the pulmonic
valve is replaced by homograft. This procedure provides children suffering with aortic
valve abnormality a hemodynamically superior valve in place of diseased valve and also
helps in facilitating somatic growth [18]. However, this technique requires double valve
replacement surgery and thus increased invasive risk. Conversely, homograft is a cadaveric
aortic valve which is sterilized using an antibiotic solution and cryopreserved in liquid
nitrogen till the time it is required. Homografts are directly implanted without using a stent
at the site of valve defect.
Bioprosthetic heart valves constructed from animal tissue valves or from the tissue
from pericardium of an animal are referred to as heterografts or xenografts. Most
commonly, porcine aortic valves and bovine pericardial tissue are utilized to build the
heterograft valves [19]. Before using the porcine valves, they are treated with varied
concentration of glutaraldehyde which sterilizes the tissue and makes it biocompatible. The
Medtronic Hancock II prosthesis and the St Jude Medical Biocor prosthesis are the example
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of glutaraldehyde fixed porcine heterografts. The porcine heterograft valve tissue is
mounted on metal stents (mostly cobalt-nickel alloy). These are called the stented valves
where the valves are sewn on to a fabric which is in turn mounted on the stent ring. The
Medtronic Freestyle valve is one of the stentless porcine bioprosthetic valves which are
available more recently that have no supporting stents. The advantage of stentless
bioprosthetic valve when compared to the stented one is that it has greater effective orifice
area (EOA) improving hemodynamics and patient survival [20]. However, stentless valves
are more prone to endocarditis, structural dysfunction and calcification and are also
technically more complex to graft than the stented ones. Porcine heterografts with good
durability can last for at least 10-15 years [18]. Pericardial valves are designed from bovine
pericardium. These valves have similar design to that of porcine heterografts

3.4 Porcine Small Intestinal Submucosa Bioscaffold:
There have been recent developments in prosthetic valve design and surgical
procedures in the past few years, but in spite of these improvements, there is no treatment
option that can permanently relieve the patient suffering from severe heart valve defects.
More specifically mechanical and bioprosthetic valves face major drawback when used as
valve replacement options in atrioventricular section after valve failure specially in infants
mainly due to size restrictions and inability to grow with the young patient [21]. Prosthetic
valves used in children often require multiple reoperations. There is a much greater need
for the development of prosthetic valves which can be used in infants and young population
where valve repair techniques are not an option.
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Extracellular matrix (ECM) derived from Porcine Small Intestinal Submucosa (PSIS)
has shown successful results when used as a patch for tissue repair in valves, vessels and
myocardium and also in the treatment of hernia, urinary system disease and refractory skin
trauma [22, 23, 24]. The PSIS scaffolds in infants and young patients suffering from cardiac
disorder has shown proof of possessing resorption properties, reendothelialization and also
replacement of PSIS material with organized collagen with no evidence of pericardial
effusions, calcification or intracardiac and intravascular thrombogenicity [24]. Tubular
PSIS-ECM tricuspid bioprosthetic valves, in 7 out of 8 ovine models, demonstrated influx
of mesenchymal cells, growth and cell-matrix configuration similar to that of mature native
valves including normal valve function [22]. There was no evident inflammation or
calcification. Lately, Cormatrix PSIS material (ECM®, CorMatrix Cardiovascular, Inc.,
Roswell, GA, USA), has obtained recognition by utilizing the scaffold in a variety of
cardiovascular surgical procedures due to its simplicity, suitable mechanical properties,
restoration properties, lower immunogenicity, absorbability and potential to promote
native tissue growth [23, 24].
PSIS contains collagen, elastin, glycosaminoglycans, proteoglycans, and growth
factors which helps in growth and healing [26]. PSIS material demonstrates FGF-2 and
TGF- β associated activities [27]. FGF-2 is a fibroblast growth factor that is linked with
limb and nervous system development, and wound healing. TGF-β belongs to the
transformation growth factor family and assists in inducing transcription of different target
genes that serve in differentiation, chemotaxis, proliferation and activation of numerous
immune cells. Both these growth factors express tissue development and differentiation in

24

PSIS-ECM scaffolds and causes wound healing and tissue remodeling. PSIS closely
mimics the normal ECM of the human dermis [26, 28].
The submucosa layer is present between the two layers, i.e. the mucosal and muscular
layers of the small intestine. Submucosa provides strength to the small intestine through
intricate fibrous matrix formed by collagen. The Cormatrix scaffold is constructed from
porcine small intestinal submucosa (PSIS) which is extracted from the intestine by
removing all the cells but keeping the complex extracellular matrix together. The scaffold
is processed and manufactured in a way that maintains the fibrous nature and porous nature
of the matrix. This helps in providing space for cell migration, proliferation, differentiation
and growth, and also helps in safe implantation. Once manufactured the acquired material
is carefully disinfected and finally decellularized. At the last phase, all the scaffolds
undergo sterilization.
In our previous study, in the Tissue Engineered Mechanics, Imaging and Materials
Laboratory (TEMIM Lab) at Florida International University (FIU), involved utilization of
Cormatrix PSIS bioscaffold valves (CorMatrix Cardiovascular, Inc., Roswell, GA, USA)
in the aortic position. This study aimed at testing tri-leaflet PSIS bioscaffolds to evaluate
their functional effectiveness by comparing them with the porcine bioprosthetic control
valves (Medtronic Freestyle, Medtronic, Minneapolis, MN) in an in-house pulse duplicator
system (Vivitro Laboratories, Victoria, Canada). Both the PSIS and bioprosthetic aortic
valves were subjected to physiological flow conditions of that of an average adult human.
The heart rate was set at 70 bpm and the stroke volume at 80 ml/beat. The results (Fig 6)
showed physiologically shaped flow and pressure data (ventricular and aortic pressure)
with no significant differences in flow and pressure when compared to that of the control
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bioprosthetic valves [29]. However, the tri-leaflet PSIS valves demonstrated higher
forward energy losses (Table 1), i.e. during the systolic phase of cardiac cycle when the
aortic valves are open for the blood to flow, as compared to the control valves [29]. The
PSIS scaffold presented some promising data however further in vitro and in vivo studies
are required to validate the complete effectiveness of the PSIS bioscaffold.

Figure 6: (a) Flow and (b) Pressure waveforms (Ramaswamy S, 2016).

Table 2: Mean ± SEM of Hydrodynamic Parameters of Aortic PSIS Valves (n=3) and
Bioprosthetic Valves (n=2) during the Systolic Phase of the Cardiac Cycle (Ramaswamy
S, 2016).
Aortic Valves

P
(mmHg)

Qrms
(ml/s)

EOA
(mJ)

PSIS (n=3)

24.0 ± 2.4

239.9 ± 44.4

0.96 ± 0.21

Forward Flow
Energy Loss*
(mJ)
286.4 ± 16.7

Bioprosthetic
(n=2)

18.1 ± 1.9

244.4 ± 3.6

1.12 ± 0.08

174.9 ± 17.4
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RF*
(%)
13.8 ±
9.8
51.3 ±
0.8

(A)

(B)
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(C)

Figure 7: (a) Trileaflet PSIS valves sutured into freshly collected porcine aortic root in
place of native valves (Ramaswamy S, 2016). (b) Pulse Duplicator System (Vivitro
Laboratories, Victoria, Canada) for assessing hydrodynamic characteristics of the valves
(Ramaswamy S, 2016). (c) Positioning of aortic and mitral valves inside the duplicator
system (Ramaswamy S, 2016).
PSIS has demonstrated to be biocompatible and has no adverse response in crossspecies transplantations [30, 31]. PSIS has been approved by the Food and Drug
Administration (FDA) for a variety of medical applications [32]. The PSIS bioscaffold
valves have the potential to deliver a solution for replacement of diseased valves in adults
and specially in infants and young patients. Nonetheless long-term effects of PSIS material
for tissue repair and replacement is still unknown and needs further examination Tissue
engineering technique in heart valves is challenging as bioscaffolds are required possessing
material properties similar to those of the native valvular tissues. Tissue engineered
materials are subjected to complex hemodynamic forces, high shear stresses and large
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transvalvular pressures during the cardiac cycle. Thus, it is of utmost importance that the
PSIS bioscaffolds are functionally optimized for the mitral valve position when critical
mitral valve disease is present, in order for valve replacement to be facilitated.
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CHAPTER 4 Methods
An ideal heart valve substitute should have excellent hemodynamic functionality. It
should possess

the following operational qualities: 1) adequate forward flow with

reasonably small transvalvular pressure drop when open; 2) prevent backward flow with
clinically acceptable small regurgitation values; 3) resist embolization 4) avoid thrombus
formation; 5) resist hemolysis 6) be biocompatible; 7) be compatible with in vivo
diagnostic techniques; 8) is deliverable and implantable in the targeted population; 9)
continues to be secured once implanted; 10) permits reproducible function; 11) retains its
functionality for an acceptable duration; 12) maintains sterility for a reasonable shelf life
prior to implantation [1].
In this particular study, as our first aim, we sutured the current clinically used geometry
of acellular PSIS bioscaffold valves in the analogous mitral position within the pulsatile
simulator. The valves were contained within Dacron conduits. We then evaluated the
hydrodynamic functionality of PSIS bioscaffold mitral valves at various native pediatric
physiological hemodynamic conditions. This was achieved in vitro in a left heart simulator
in our laboratory. Subsequently, in aim 2, the thickness of PSIS bioscaffold was fine-tuned
to optimize the following hydrodynamic metrics: 1) valve pressure gradient, 2) forward
flow, 3) energy losses and 4) regurgitation volume, with minimal PSIS material usage.
Specifically, a thinner PSIS mitral valve (2ply) was evaluated as compared to the PSIS
mitral valve assessed in aim 1 (4ply)
4.1 Valve Preparation:
PSIS bi-leaflet bioscaffold valves (n=6) and porcine conduitless tri-leaflet bioprosthetic
control valves (Edwards Lifesciences, Irvine, CA) (n=4) were tested in an in-house pulse
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duplicator system (Vivitro Laboratories, Victoria, Canada). Bi-leaflet PSIS valves
assembled from sheets of PSIS bioscaffold (Cormatrix, Roswell, GA) were manually
sutured in Dacron conduits by referring to the procedure previously utilized in heart valve
repairs [2] (Fig. 9). In short, to construct a bi-leaflet valve, a patch of extracellular matrix
(Cormatrix, Roswell, GA) was folded over the top edge of the sheet to form a cuff. A dilator
of the preferred size was then used to wrap the same sheet around it. The folded-over
annulus of the bioscaffold valve was attached with a running stitch to create a sewing cuff,
and the free edges of the wrapped material were cut to size over a dilator. The PSIS material
was then sewn together in a continuous fashion to form a tube. Following this, a running
5-0 Prolene suture was used to suture the bioscaffold to the proximal end of the Dacron
tube.

Figure 8: Appearance of the custom made bileaflet PSIS valve after construction
(Bibevski S, 2015).
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These constructs were subsequently immersed in a protease inhibitor cocktail (Sigma
Aldrich, St. Louis, MO), with phosphate buffer solution (PBS) as the solvent. Valve
holders were designed (Solidworks, Waltham, MA) and customized for each PSIS valve
to improve the solidity of the valves during in vitro hydrodynamic testing (Fig. 11). Precise
measurements of the dimensions of each valve were recorded and the computer-aided
drawing (CAD) of the valve holder was custom-made to accurately accommodate the
valves. The valve holders were then fabricated using white-colored, Poly-L-lactic acid raw
filament material (Dynamism, Chicago, IL) via 3-dimensional printing (Makerbot
replicator series, Makerbot Industries LLC, Brooklyn, NY). Once the holders were printed,
the valves were secured compactly to the holders by suturing around the annulus and sinotubular junction (STJ) of the valve. The secure valve was then press-fitted into the mitral
location within the pulse duplicator system.

Figure 9: Bileaflet Porcine Small Intestine Submucosa valve for mitral valve testing. The
two leaflets are indicated by the arrows.
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Figure 10: Edwards Lifesciences Bioprosthetic Valve serving as control valve.

Figure 11: Valve Holder designed in SOLIDWORKS (Ramaswamy S, 2016).
4.2 Hydrodynamic Assessment:
We have utilized a commercially available pulse duplicator unit (Vivitro System,
Victoria, BC) in our previous experiments to evaluate flexible-leaflet valve implants and
to assess functionality of PSIS tri-leaflet aortic valves [3, 4] (Fig. 12). We used the same
pulse duplicator system which accommodates bi-leaflet and tri-leaflet valve constructs and
in-turn evaluates mitral and aortic valve hydrodynamic metrics respectively (e.g. energy
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losses, regurgitation volume, etc.). The mechanical component of the pulse duplicator
system comprises of atrial, ventricular and aortic units, which mimic those to left side of
the heart, a piston pump, and a computer-based user interface (ViViTest Software, Vivitro
Laboratories) for waveform specification and data acquisition/analysis. The system
simulates physiologically-relevant circulatory environments defined by the user. To enable
the measurement of flow and pressure data, a flow probe was positioned at the inlet of the
mitral valve and two piezoresistive transducers (Model 6069, Utah Medical Products, Inc.,
Midvale, UT) pressure transducers at atrial and ventricular location in the system. To
measure instantaneous flow rate, we placed an electromagnetic-based flow probe,
connected to a flow meter (Carolina Medical Electronics), between the atrial and the
ventricular chamber of the pulse duplicator just proximal to the inlet of the mitral valves.
The spatial placement of the flow probe and pressure transducers was the same for all the
valves tested.
In the current study, for both the aims, PSIS valves were mounted in the mitral position
within the test unit, whereas a bi-leaflet mechanical valve was mounted in the aortic
position to complete the loop (Fig. 13). A bi-leaflet mechanical valve (St. Jude Medical,
St. Paul, MN) was mounted in the aortic position for all valve tests conducted (Fig. 13).
Finally, a 0.9% saline solution was introduced through the atrial chamber, to fill the loop
with fluid, in accordance with hydrodynamic valve testing industrial practice using
international Organization for standardization guidelines (ISO 5840). The system was
checked to confirm there were no observable leaks. Before commencing the experiment,
we calibrated the entire system.
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Calibration was performed for accurate pressure and flow output readings, as per ISO
5840 specifications for prosthetic valves [5]. The calibration process is a step-by-step
procedure. It is very important to calibrate the entire system before using it every time.
There are four different calibration steps. These steps involve zero offset measurements,
pump calibration, calibration of the flow meter and flow probe, and calibration of the
pressure sensors. The ViViTest software is used to accomplish this task leading the
calibration values shown in the sensor calibrations panel. Before starting the calibration
procedure, an open spacer ring was placed in the mitral position and the opposite side
(aortic position) was closed using a solid plug. No valves were introduced during the
calibration phase. We introduced the flow probe in the mitral location, i.e. site of interest.
Once the system was set-up, we filled the assembly with 0.9% saline solution through the
atrium chamber and the pump control was set using ViViTest software to desired levels
(Heart rate = 70bpm and S50 waveform).
The first step was to zero any offset of the sensor values. Zero values for the sensors
were calculated for the pressure, pump and flow sensors on a static system open to
atmosphere. After zeroing the values, pump calibration was carried out in order to scale
the stroke volume displayed in the software to match the stroke volume displayed on the
SuperPump Controller. This was done by dialing up the stroke volume on the SuperPump
through the desired testing range. Once the pump was calibrated, we proceeded towards
the calibration of the flow probe and flow meter. It involved two steps, an external
adjustment of the flow meter prior to flow calibration in ViViTest and tuning of the flow
probe using the ViViTest. The flow meter tuning was executed by switching ON the flow
meter and then adjusting the ZERO, NULL, BALANCE, and + or – switches respectively

37

as per the system guidelines. After this step the flow probe was calibrated by pumping the
saline solution through the probe lumen at heart rate of 70bpm and stroke volume of 80
ml/beat. With this calibration, the flow rate through the transducer was made directly
proportional to the piston displacement signal differentiated with respect to time (dL/dt).
The dL/dt signal is an output from the SuperPump Controller. The last step was to calibrate
the pressure sensors. The pressure transducers were mounted on a manifold and first
exposed to the atmosphere to establish the lower end of the pressure range. The low and
high pressures were chosen to span the expected working range of the transducers, in this
case 0 to 200 mmHg. Then a large syringe and a digital manometer was used to apply and
measure the upper range pressure, i.e. 200 mmHg. Subsequently the pressure sensors were
introduced into the system in their specified location and were introduced to the static flow
before saving the values. After all the calibration processes were completed, the calibration
parameters were saved and used for data acquisition.
A pulsatile waveform representing a physiological flow profile (S50 waveform, Vivitro
Laboratories) and which has been previously utilized for hydrodynamic studies using the
same pulse duplicator system [4, 6] was selected for all tests conducted. After switching
on the flowmeter, the amplitude of the pump regulator was slowly increased until the stroke
volume reached 80 mL/beat.
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Figure 12: Pulse duplicator system (Vivitro Laboratories, Victoria, Canada).

Figure 13: Mitral valve configuration in the Pulse Duplicator System.
4.2.1 Aim 1:
Our study was specifically designed to provide potential valve replacement alternatives
for infants and small children. PSIS material has the ability to provide somatic growth
along with biodegradation of the material, which is an important property for pediatric
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populace. However, it was important to prove the hydrodynamic functionality of this
bioscaffold.
For Aim 1, we were interested in testing the PSIS bioscaffold mitral valves (n=5) at
pediatric conditions as the main goal of this study is to potentially develop a valve
replacement solution for infants and children. The established parameters incorporated two
sets of flow profiles depicting left circulatory conditions in the pediatric (Table 2(a) & (b)).
A physiological waveform representative of the pumping action of the left ventricle was
selected (in the case of the Vivitro system the S50 waveform was chosen for all
hydrodynamic tests) to drive flow through the loop [6]. At the end of each run, data was
recorded over 10 continuous cycles
Table 3(a): Varying heart rates at constant stroke volume = 40 ml/beat.
Heart Rate (bpm)
110
125
140

Pediatric Hemodynamic Conditions at
Constant Stroke Volume

Table 3(b): Varying stroke volumes at constant heart rate = 145 bpm.
Stroke Volume (ml/beat)
20
25
30

Pediatric Hemodynamic Conditions at
Constant Heart Rate

4.2.2 Aim 2:
Motivation: The rationale behind this aim was to decrease the demand on body for
native tissue replacement once the PSIS bioscaffold degrades. We conducted this study to
test the efficacy of these 2ply PSIS valves against 4ply PSIS and bioprosthetic valves
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Similar to Aim 1, the study for Aim 2 was conducted by suturing a bi-leaflet valve
configuration in the mitral position in the simulator and exposing the valves to the best
selected pediatric mitral valve hemodynamic conditions. For our first aim, we tested 4-ply
PSIS mitral valves (n=5) which were at 100 % thickness. The leaflet thickness was finetuned to establish robust functionality for the mitral position with minimal use of
bioscaffold material. The thickness of the valves was reduced by half, that is we used 2ply valves as other set of valves (thickness reduced from 100% to 50%). This approach has
the potential to reduce the burden on the host since less tissue is required to fill a smaller
scaffold space. It is important to maintain robust functionality of PSIS-valves but with
minimal use of material thereby reducing the demand for de novo replacement tissue
growth in the patient. Therefore, it was critical to conduct functional hydrodynamic testing
of these valves using the same pulsatile simulator that is used to evaluate clinicallyapproved, flexible bio-prosthetic valves, to account for measurement differences that may
be system dependent.
4.3 Data Analysis:
As mentioned before, we analyzed the data over 10 cycles for each PSIS and
bioprosthetic valves. We investigated 40 runs (r = 40) for 4ply PSIS valves (n = 4), 40 runs
(r = 40) for bioprosthetic control valves (n = 4) and 20 runs (r = 20) for 2ply PSIS valves
(n = 2). Our pulse duplicator system (Vivitro Laboratories, Victoria, Canada) currently
allows us to capture 10 cycles at a time. We have presented a table of mean +/- SEM of
atrial, ventricular and forward flow values at one of the conditions (140 bpm, 40 ml/beat),
over the above-mentioned runs (Table).
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Table 4: Mean ± SEM of ventricular, atrial and forward flow values for the entire cycle at
heart rate of 140 bpm and stroke volume of 40 ml/beat for 2ply valves (r = 20 runs), 4ply
(r = 40 runs) and bioprosthetic valves (r = 40 runs).
Valves
2ply
4ply
Bioprosthetic

Ventricular Pressure (VE)
(mmHg)
67.8 ± 0.42
55.2 ± 1.02
28.6 ± 0.87

Atrial Pressure (AT)
(mmHg)
10.9 ± 0.3
9.46 ± 0.49
6.5 ± 0.43

Flow (ml/s)
83.9 ± 1.53
78.9 ± 1.89
78.8 ± 1.64

The mean pressure and flow calculations observed here are robust with very small
errors. Therefore, we believe for short term predictions of hydrodynamic functionality
across the valve, 10 cycles are adequate.
We calculated the following hydrodynamic metrics for each of the valves tested;
pressure gradient (ΔP; mmHg), root mean square flow rate (Qrms; mL/s), effective orifice
area (EOA; cm2), closing energy loss, (mJ) and regurgitation fraction (% RF). Pressure
gradient was directly computed from the mean pressure profiles during the diastolic phase
when the mitral valve is open. Similarly, forward flow was computed during diastolic
phase, directly from flow profiles of the mitral valves. However, RF and closing energy
loss were computed during the systolic phase when the mitral valve is closed. The forward
flow (Qrms), effective orifice area (EOA) [7, 10] and closing energy loss for the mitral
valves [8, 9, 10] was defined as follows:
Equation 1

=

+
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+ ⋯+

Equation 2
=

51.6 ∗ √∆

Equation 3

=

∆

∗

where t0 = beginning and t1 = end respectively of the systolic phase of the cardiac
cycle, ∆p(t) is the pressure gradient between atrial chamber and ventricular chamber over
the cardiac cycle and q(t) is the pulsatile flow rate of the fluid. Ten cycles were recorded
for each PSIS and bioprosthetic valve tested and data were averaged for each group.
4.4 Statistics:
The t test was used to establish any significant differences in hydrodynamic parameters
between the 4ply PSIS bioscaffold group and the Control group in aim 1, while an ANOVA
test was used for aim 2 where we compared 2ply PSIS bioscaffold valves vs 4ply PSIS
bioscaffold valves vs bioprosthetic valves. A difference between the two groups was
considered statistically significant when p<0.05. All hydrodynamic metrics were presented
in Mean ± Standard error of the mean (SEM).
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CHAPTER 5 Results and Discussion: Aim 1
The mitral valvular system is an intricate anatomical and functional entity. Different
congenital malformations may affect the mitral valve and can occur as an isolated defect
or in combination with other complex left sided lesions [1]. In one echocardiographic
study, congenital mitral valve malformation was detected in almost 0.5% of the 13,400
subjects [2]. Mitral valve repair is always desirable when possible over replacement [3,4].
Generally critical congenital mitral valve pathology in infants and children poses frequent
challenges to pediatric cardiac surgeons, as mitral valve replacement (MVR), being
inevitable, increases the rate of morbidity in the pediatric population significantly [5].
When reconstruction fails or is not feasible, valve replacement becomes unavoidable.
The pediatric and neonatal population with mitral valve disease has limited choices for
prosthetic valve replacement because of the unavailability of suitable prosthetic valve
alternatives and restrictions with respect to patient to prosthetic dimension [7]. The major
drawback with the current prosthetics is their inability to grow with the patient, thus
requiring multiple valve replacement surgeries as the child grows. Implantation of large
prosthetic mitral valves in the supra annular position and Ross II procedure are the two
available options for infants and children suffering from mitral valve defect. However,
these options have their drawbacks specially in pediatric patients as use of prosthetic valves
is associated with a high rate of thromboembolic adverse events. Mechanical prosthetic
valves are durable but lead to clotting of the blood, thus requiring life-long anticoagulation
treatment. Bioprosthetic valves and Homografts on the other hand do not require life-long
anticoagulation, but are less durable as compared to mechanical valves. Also, these valves
do not provide for somatic growth and thus there is always a need of multiple valve
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replacement surgeries thus leading to further complications. The Ross II procedure also
have limitations in terms of somatic growth [8, 9].
For pediatric application, an ideal valve should support somatic growth, i.e., grow with
the patient, have low risk of thrombosis and should fit into the small annular sizes of infants
and children. In this study, we proposed a technique of mitral valve replacement with
porcine small intestinal sub-mucosal bioscaffold (PSIS) valve, which is custom handmade
and has the potential to be implanted in an infant and a small child. As previously stated,
compassionate care cases involving neonates suffering with congenital critical valve
disease, our collaborators have already employed this bioscaffold for valvular replacement.
According to our understanding we are the only group to have utilized this technique in
pediatric patients for the management of congenital heart valve disease in infants and
children. In Vivo studies have reported that the valves have performed well, with lowered
transvalvular pressure gradients and not necessitating anti-coagulant therapy [10, 11].
PSIS bioscaffold as described before is an extracellular matrix having acellular,
biodegradable soft tissue material properties which has the potential to remodel itself after
implantation and leave in its place a healthy and organized native tissue. PSIS possesses
the molecular make-up of native cardiovascular structures, such as collagen and elastin. It
also possesses fibronectin and laminin adhesion glycoproteins, glycosaminoglycans
(GAGs) and matricellular proteins (e.g. thrombospondins, osteopontin, and tenascins).
These properties make it suitable for cardiovascular regenerative applications especially in
infants and small children.
Although some results have been positive, substantial uncertainties still remain. There
are reports that show adverse effects of PSIS bioscaffold. The first adverse results were
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published by Weber and colleagues. The results exhibited pseudoaneurysm formation with
disorganized collagen in patients who had undergone carotid artery patch angioplasty with
PSIS bioscaffold [12]. In the other study, it has been reported presence of hemodynamically
significant lesions at the site of the PSIS implantation which required reoperation, in 6 of
25 patients receiving PSIS patches during cardiac operations [13]. Explanted specimens
established an intense inflammatory response characterized by numerous eosinophils,
histiocytes, and plasma cells, accompanied by granulation tissue and fibrosis [13]. Few
studies have reported the inflammatory response to CorMatrix PSIS bioscaffold. In couple
of studies PSIS scaffold inflammation was observed in the graft application. Similar
findings of an intense inflammatory response to the material was noticed in the aortic patch
along with early critical disintegration and aneurysm formation [14].
In one of the pediatric studies by Zaidi et al, histologic evaluation of 11 Cormatrix PSIS
aortic and mitral valves was presented [15]. These valves were explanted due to ﬁxation,
thickening, prolapse of the leaflets, dehiscence and folded PSIS patch. The 9 months
implantation results showed no remodelling in analogous to native valves having three
layers along with the inflammatory response. In other study, implants obtained from 11
pediatric patients relating to 2 mitral valves, 2 aortic valves, 8 outflow septal or conduit
patches, tissue necrosis was observed in 5 cases along with chronic inflammation [16]. One
of the surgical procedures reported delamination of the bioscaffold patches which caused
continued washing of the PSIS material [17]. PSIS valves are scaffolds that are designed
by laminating multiple layers together. The delamination can also lead to blood flow loss
due to blood being potentially captured within the multiple laminations, resulting in failure
of the valves.
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Cardiovascular applications of CorMatrix PSIS patch is comparatively new. There are
currently mixed reviews about this bioscaffold. However, these studies have certain
limitations mainly with regards to lack numbers of subjects and organized reporting. In
spite of these, the growth prospects and mid to long term potential has not been
systematically, nor scientifically explored. Here our aim was to assess the functionality of
PSIS bioscaffolds in mitral valve replacement application. We understand and recognize
the significance of performing a systematic assessment of PSIS mitral valve functionality
in terms of its opening and closing properties, before this expertise can be made available
widely for all the patients as a first choice and not just used for compassionate care cases.
To achieve this purpose, PSIS bioscaffold valves were examined under the
physiologically expected hydrodynamic conditions of native mitral valve from pediatric
population. To best assess these bioscaffold valves in vitro under physiological conditions
we utilized a Vivitro pulse duplicator available in our laboratory (Vivitro Laboratories,
Victoria, BC). It has been modified to facilitate these testing and used before to test flexible
leaflet valve and PSIS aortic bioscaffold valve implants [18, 19]. Thus, with this device,
we could assess hydrodynamic functionality of sutured PSIS bioscaffold valves which were
contained within a Dacron conduit.
Bi-leaflet PSIS bioscaffold valve templates (Cormatrix, Roswell, GA) were assembled
manually into the Dacron conduit as described in the methods section and which has been
used to treat clinical cases for critical congenital mitral and aortic valve diseases
respectively. The valves were then secured to the custom-made valve holder by progressing
with suturing along the circumference of the holder. The holder with the sutured PSISvalve was mounted in the mitral position within the test unit, whereas a bi-leaflet
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mechanical valve was mounted in the aortic position, within the pulse duplicator system
(Vivitro Laboratories, Victoria, BC). A 0.9% saline solution was introduced through the
atrium chamber, to fill the loop with fluid. To enable the measurement of flow and pressure
data, a flow probe was positioned at the inlet of the mitral valve and two pressure
transducers at atrial and ventricular location in the system. Calibration was performed to
warrant for accurate pressure and flow output readings. After the system was checked for
any observable leaks, testing was initiated. The established parameters (heart rate, stroke
volume) incorporated two sets of flow profiles depicting left circulatory conditions in the
pediatrics.
A physiological waveform representative of the pumping action of the left ventricle
was selected (in the case of the Vivitro system the S50 waveform was chosen for all
hydrodynamic tests) to drive flow through the loop [19]. At the end of each run, data was
recorded over 10 continuous cycles.
Results and Discussion:
Results were compared to commercially available porcine bioprosthetic mitral heart
valves (control group).
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Figure 14: Mean temporal (A, B) pressure and flow waveforms at 110 bpm and 40
ml/beat, (C, D) pressure and flow waveforms at 125 bpm and 40 ml/beat, (E, F) pressure
and flow waveforms at 140 bpm and 40 ml/beat, (G, H) pressure and flow waveforms at
145 bpm and 20 ml/beat, (I, J) pressure and flow waveforms at 145 bpm and 25 ml/beat,
(K, L) pressure and flow waveforms at 145 bpm and 30 ml/beat measured for 4ply PSIS
valves (n=4) and Bioprosthetic valves (Edwards Lifescience) (n=4) tested in the mitral
position in our pulse duplicator system (Vivitro Laboratories).
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Upon completion of flow and pressure profiles we computed the following
hydrodynamic metrics: pressure gradient, forward flow, effective orifice area of the valve,
systolic energy losses and regurgitation volumes. Our findings were as following results.
Results are summarized in Table 3(a), 3(b), 4(a) and 4(b).
Table 5(a): Mean ± SEM of Hydrodynamic Metrics of PSIS Mitral Valves (n=4) at constant
stroke volume of 40 ml/beat.
Heart Rate
(bpm)

ΔP(diastolic)
(mmHg)

Peak
ΔP(systolic)
(mmHg)

Qrms
(ml/s)

EOA
(cm2)

Systolic
Energy
Loss (mJ)

RF

110

4.64 ±
0.45

78.5 ±
3.19

135.6 ±
17.3

1.22 ±
0.08

20.6 ± 4.1

4.25 ±
1.8

125

6.02 ± 0.3

75.4 ±
3.46*

148.6 ±
6.88

1.26 ±
0.03

29.3 ± 5.87

3.54 ±
0.64

140

6.17 ±
0.75*

115.9 ±
3.74*

159 ±
7.89

1.31 ±
0.2

39.1 ± 3.12

4.38 ±
0.25

(%)

Table 5(b): Mean ± SEM of Hydrodynamic Metrics of porcine trileaflet Bioprosthetic
(Edwards Lifescience) (n=4) at constant stroke volume of 40 ml/beat.
Heart Rate
(bpm)

ΔP(diastolic)
(mmHg)

Peak
ΔP(systolic)
(mmHg)

Qrms
(ml/s)

EOA
(cm2)

Systolic
Energy
Loss (mJ)

110

4.32 ±
0.15

91.8 ± 5.47

127.1 ±
4.21

1.19 ±
0.07

14.5 ± 2.27

3.44 ±
0.72

125

5.92 ±
0.32

44.6 ±
4.15*

157.4 ±
2.42

1.35 ±
0.05

19.2 ± 4.8

3.2 ±
0.37

140

5.34 ±
0.24*

72.8 ± 4.4*

178.2 ±
6.52

1.56 ±
0.09

29.8 ± 3.76

3.71 ±
0.68

Note: ‘*’ indicates statistical significance.
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RF
(%)

Table 6(a): Mean ± SEM of Hydrodynamic Metrics of PSIS Mitral Valves (n=4) at constant
heart rate of 145 bpm.
Stroke ΔP(diastolic)
Volume (mmHg)
(ml/beat)

Peak
ΔP(systolic)
(mmHg)

Qrms
(ml/s)

EOA
(cm2)

Systolic
Energy
Loss (mJ)

RF
(%)

20

4.24 ±
0.27

28.4 ±
2.12*

99.4 ±
2.80

0.92 ±
0.04

8.88 ± 1.67

3.04 ±
0.38

25

4.99 ± 0.3

44.9 ±
3.07*

119.4 ±
3.21

0.99 ±
0.07

17.2 ± 4.11

3.59 ±
0.51

30

5.6 ± 0.38

54.6 ±
2.66*

137.3 ±
1.35

1.12 ±
0.09

30.82 ±
2.77

4.14 ± 0.4

Table 6(b): Mean ± SEM of Hydrodynamic Metrics of porcine trileaflet Bioprosthetic
(Edwards Lifescience) (n=4) at constant heart rate of 145 bpm.
Stroke ΔP(diastolic)
Volume (mmHg)
(ml/beat)

Peak
ΔP(systolic)
(mmHg)

Qrms
(ml/s)

EOA
(cm2)

Systolic
Energy
Loss (mJ)

RF
(%)

20

4.05 ± 0.7

17.7 ±
2.56*

103.2 ±
4.6

1.01 ±
0.1

6.29 ± 0.08

2.65 ± 0.5

25

4.4 ± 0.32

27 ± 2.79*

120.9 ±
2.85

1.03 ±
0.06

11.8 ± 1.1

2.9 ± 0.49

30

5.14 ±
0.41

28.2 ± 4.3*

145 ±
3.56

1.2 ±
0.04

20.68 ± 3.9

3.08 ± 1.7

Note: ‘*’ indicates statistical significance

As stated, we assessed the PSIS bi-leaflet bioscaffold valves for acute functionality in
the mitral position at 6 different pediatric physiological conditions of stroke volume and
heart rate. We compared PSIS mitral valves with the bioprosthetic control group at all
conditions. For pediatric conditions results demonstrated similar physiological pressure
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and flow data when compared with trileaflet bioprosthetic valves. However, we see some
discrepancies in the ventricular pressure between the two group as we increase the heart
rate.
At lower pediatric relevant heart rate of 110 bpm, the pressure and flow waveforms
were very similar, but as we increased the heart rate keeping the stroke volume constant at
40 ml/beat, we observed differences particularly in the ventricular pressure. In the case of
varying stroke volume at the constant heart rate of 145 bpm, even at the lower stroke
volume we saw some key difference in both the ventricular pressure and the flow rate. As
we increase the stroke volume, we noticed these differences continued. Thus, at higher
heart rates and higher stroke volume, the differences in the ventricular pressure and some
differences in the flow rate were noticeable. Peak systolic pressure gradient for 4ply PSIS
valves during constant stroke volume ranged from 78.5 mmHg to 115.9 mmHg and for
bioprosthetic valve it ranged from 44.6 mmHg to 91.8 mmHg. At constant heart beat the
systolic pressure gradient range for 4ply PSIS valves was from 28.4 mmHg to 54.6 mmHg
and for bioprosthetic valve 17.7 mmHg to 28.2 mmHg.
The normal systolic pressure for adult is 100-140 mmHg [20] and for child before
adolescent is 60-120 mmHg which gradually increases as the child grows [21]. We
observed that peak systolic pressure gradient for PSIS valves increased progressively with
the increase in the cardiac output under pediatric conditions and were close to the reference
values. Conversely, for the bioprosthetic valves we noticed that the peak systolic pressure
gradient was relatively low. The peak systolic gradient for bioprosthetic valve was
statistically lower than that of the PSIS valves at all conditions, except at 110 bpm at 40
ml/beat. However, the mitral valves in both the groups were efficiently closed during the
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systolic phase as can be observed from the RF (%), which was low for both PSIS and
bioprosthetic valves. The low peak pressure gradient during the systolic phase may be due
to the material properties of the bioprosthetic scaffold. In our previous publication [19], we
reported mean Young’s modulus of both the PSIS and chemically-fixed bioprosthetic
values. Mean Young’s modulus for bioprosthetic valves was ~43 MPa [24], whereas PSIS
valve tissues were comparatively stiffer circumferentially with modulus of elasticity of
101.99 ± 58.24 MPa (but only about 9.18 ± 1.81 MPa radially) [25, 26]. We speculate that
the bioprosthetic valves being less stiff circumferentially may have potentially led to a
lower peak systolic gradient.
EOAs were comparable at all 6 different conditions (p<0.05) which permitted an
objective comparison in acute hydrodynamic functionality between the two groups. ΔP was
almost similar in both the groups and statistically insignificant in all the cases, expect at
140 bpm and 40 ml/beat. Even though the ΔP was significantly higher at this condition, it
was very close to the acceptable clinical value [22]. Forward flow was dominant in the
diastolic phase when the mitral valve is open with relatively low to no forward flow during
systole. Forward flow (Qrms) was found to be not significantly different (p>0.05) between
the two groups thus resulting in robust flow data. We noticed slightly greater regurgitation
fraction (RF) in PSIS group. However, RF was statistically insignificant (p>0.05) in
comparison to the bioprosthetic group and also in the acceptable clinical range [23].
Although the systolic energy losses observed in both groups at 6 different conditions
were not statistically significant, the PSIS-valves exhibited higher energy losses during the
systolic period compared to the bioprosthetic controls. We noticed that as we increase the
stroke volume or the heart rate (Fig 15 (a), (b)), the net effect of the energy loss was the
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same in both the 4ply PSIS valves and the bioprosthetic valves. When we computed the
cardiac output, and looked at the percent increase in the energy loss (Fig 15 (c)), the net
effect of the energy loss in 4ply PSIS valves was again consistent as that of the
bioprosthetic control group, i.e. increase by approximately 3.5 times with doubling of the
cardiac output in both groups.

(a)
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(b)

(c)
Figure 15: % increase in PSIS and Bioprosthetic energy loss during systolic phase vs. (a)
% increase in heart rate at constant stroke volume of 40 ml/beat. (b) % increase in stroke
volume at constant heart rate of 145 bpm. (c) cardiac output (ml/min).
Nevertheless, it is obligatory that the PSIS valves grow longitudinally and have
symmetric growth after implantation. This accurate somatic growth is the must to mitigate
or to support the normal rise in the energy losses. However, if the growth is inadequate and
random or if there is improper growth of the PSIS bioscaffold, this will adversely affect
the energy loss parameter, resulting in greater energy losses and subsequent failure of the
PSIS mitral valve, ultimately causing increased workload on the heart.
We evaluated energy loss during the systolic phase as most of the mitral valve disease
is associated with mitral regurgitation or prolapse as compared to mitral stenosis. As
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Energy loss may serve as a biomarker indicating improper closing of the mitral valve
during the systolic phase and potentially long-term detriment to heart function. Sufficient
energy applied by the contraction of the left ventricular chamber helps in the proper closing
of the mitral valves, thus avoiding regurgitation or prolapse. The mitral valves that do not
close aptly may lead to more vicious pumping of the left ventricle, thus resulting in higher
energy losses. This may eventually lead to heart failure.
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CHAPTER 6 Results and Discussion: Aim 2
It is important for infants and children that a tissue engineered or biocompatible heart
valve prosthesis possess appropriate hemodynamic profile, low thrombogenic potential,
provide somatic growth and an integral part of patient’s native tissue over time [2]. One
promising bioscaffold material for the assembly of such a valve is an acellular bioscaffold
composed of non-crosslinked extracellular matrix (ECM) derived from porcine small
intestinal submucosa (PSIS). This material has shown bioresorbable capabilities of in vivo
native cellular recruitment and repopulation in a broad range of tissues, including cardiac
tissue [3-7]. Promising in vivo growth, both circumferential and longitudinal, has also been
reported in a study that utilized PSIS material as an interpositional vena cava graft in a
growing piglet. The longitudinal growth of the PSIS graft was reported to be around 147%
and circumferential around 184% over a 3-month time period [8].
When implanted in the body, it has been observed that the degradation of the ECM
scaffold by immunomodulatory, pro-remodeling macrophages produces biochemical cues
that attract progenitor cells. and, in concert with the surrounding biomechanical and fluiddynamic environment, induce progenitor-cell proliferation and phenotypic maturation [5,
9, 10]. Products of matrix degradation also confer antimicrobial properties on the ECM
material [11] and lack of crosslinking reduces its propensity for inflammation and
calcification [5]. With respect to the physical architecture of a bioprosthetic heart valve,
experimental and clinical studies over the past 2 decades have demonstrated the superiority
of a tubular design in terms of restoring normal transprosthetic flow dynamics and stress
distribution on the valve leaflets, regardless of the type of tissue or other material used to
construct such tubular valves [12].
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As stated in the previous chapters in this thesis, the main focus of this study was the
determine hydrodynamic function of a PSIS mitral valve design for valve replacement in
infants and children suffering from severe congenital heart valve disease, which can
accommodate somatic growth. PSIS is a decellularized bioscaffold from the submucosal
layer of the porcine small intestine. A key attractive feature of PSIS bioscaffold is its
biodegradability with de novo replacement of tissues exhibiting the cardiovascular
phenotype [13, 14]. The specific objective of aim 2 in this investigation was to reduce the
thickness of the PSIS-assembled mitral valves from ~ 320 µm (4 ply) to ~ 166 µm (2 ply),
which results in an overall percent volumetric reduction of ~ 54 %. In theory, this reduction
contributes towards reduction in burden on the body to produce newer valvular tissues.
Moreover, another potential benefit of a thinner valve would be a decreased risk of leaflet
delamination which would be detrimental in the context of increased thrombus risk and
interfering with unidirectional blood flow.
Nonetheless, an important aspect of thickness reduction, is the critical need to continue
to improve upon or at least maintain robust hydrodynamic functionality of the bioscaffold
with minimal use of PSIS material. To accomplish this task, it is important to conduct
functional testing of 2ply bioscaffold mitral valves using the same pulse duplicator system
(Vivitro Laboratories, Victoria, BC) that was used to evaluate PSIS bioscaffold of 4 ply
mitral valve thickness in aim 1, which is routinely used in the FDA approval process for
commercially-available mechanical and bioprosthetic valves. All the steps carried out were
the same as mentioned before for the 4ply valves. However, the parameters selected were
only 2; (i) Heart rate of 140 bpm and stroke volume of 40 ml/beat. (ii) Heart rate of 145
bpm and stroke volume of 20 ml/beat. We sutured the 2ply PSIS valves into custom
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adapters similar to that of the 4ply valves. The adaptor with the secured valves was then
press-fit into the mitral position into the pulse duplicator system for subsequent testing.
The testing was performed similarly as in first aim and 10 cycles were recorded for
each valve and at each set of parameters. Figure 15 (A-D) depicts the pressure and flow
waveforms for 4ply PSIS vs. 2ply PSIS mitral valves. Figure 15 (A, B) are the pressure
and flow waveforms for the PSIS valves tested at heart rate of 140 bpm and stroke volume
of 40 ml/beat. Likewise, pressure and flow plots for PSIS valves tested at heart rate of 145
bpm and stroke volume of 20 ml/beat are illustrated by figure 15 (C, D).

Results and Discussion:

(A)

(B)
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(C)

(D)

Figure 16: Mean temporal (a) pressure waveforms at 140 bpm and 40 ml/beat, (b) flow
waveforms at 140 bpm and 40 ml/beat, (c) pressure waveforms at 145 bpm and 20
ml/beat and (d) flow waveforms at 145 bpm and 20 ml/beat measured for 4ply PSIS
valves (n=4) and 2ply PSIS valves (n=2) tested in the mitral position in our pulse
duplicator system (Vivitro Laboratories).

Table 7(a): Mean ± SEM of Hydrodynamic Metrics of 2ply PSIS mitral valve (n=2) vs 4ply
PSIS mitral valve (MV) (n=4) vs porcine trileaflet Bioprosthetic valve (BPV) (Edwards
Lifescience) (n=4) at heart rate of 140 bpm and stroke volume of 40 ml/beat.
MV

ΔP(diastolic)
(mmHg)

2ply

6.56 ±
0.34
6.17 ±
0.75
5.34 ±
0.24

4ply
BPV

Peak
ΔP(systolic)
(mmHg)
137.4 ±
1.59*
115.9 ±
3.74
72.8 ±
4.4

Qrms
(ml/s)

EOA
(cm2)

262.3 ±
29.8*
159 ±
7.89
178.3 ±
6.52

1.97 ±
0.18
1.31 ±
0.2
1.56 ±
0.09

Note: ‘*’ indicates statistical significance.
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Systolic
Energy Loss
(mJ)
25.2 ± 2.81
39.1 ± 3.12
29.8 ± 3.76

RF
(%)
7.03 ±
0.82*
4.38 ±
0.25
3.71 ±
0.68

Table 7(b): Mean ± SEM of Hydrodynamic Metrics of 2ply PSIS mitral valve (n=2) vs 4ply
PSIS mitral valve (MV) (n=4) vs porcine trileaflet Bioprosthetic valve (BPV) (Edwards
Lifescience) (n=4) at heart rate of 145 bpm and stroke volume of 20 ml/beat.
MV

ΔP(diastolic)
(mmHg)

2Ply

4.27 ±
0.96
4.24 ±
0.27
4.05 ± 0.7

4Ply
BPV

Peak
ΔP(systolic)
(mmHg)
55.1 ±
1.4*
28.4 ±
2.12
17.7 ±
2.56

Qrms
(ml/s)

EOA
(cm2)

165.4 ±
14.2*
99.4 ±
2.80
103.2 ±
4.6

1.49 ±
0.21*
0.92 ±
0.04
1.01 ±
0.1

Systolic
Energy Loss
(mJ)
6.18 ± 3.11
8.88 ± 1.67
6.29 ± 0.08

RF
(%)
5.87 ±
0.75*
3.04 ±
0.38
2.65 ± 0.5

Note: ‘*’ indicates statistical significance.
Hydrodynamic assessment of 2ply PSIS bioscaffold mitral valves also revealed
hydrodynamically robust data both in terms of flow and pressure in both the cases. In the
first set of data at heart rate of 140 bpm and stroke volume of 40 ml/beat, when compared
with the 4ply PSIS mitral valves and the control group we noticed that the Q rms through the
2ply PSIS valve was significantly greater (p<0.05) than the other two groups. Moreover,
we found that the RF was significantly higher (p<0.05) in 2ply valves when compared to
4ply and bioprosthetic valves but within clinical range [15].
In the other data set at heart rate of 145 bpm and stroke volume of 20 ml/beat, we again
observed significantly higher Qrms (p<0.05) in 2ply valves as compared to the 4ply valves
and bioprosthetic valves. Likewise, similar to the first case, RF was significantly higher
(p<0.05) in 2ply valves. Moreover, EOA was seen to be significantly larger (p<0.05) in
2ply bioscaffold valves at 145 bpm and at 20 ml. More flow through 2ply valves as
compared to 4ply valves may indicate more opening of the bileaflet valves during the
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forward flow. Even though RF is greater, but when compared to clinical values it’s still
trivial [15].
Similar to aim 1, we again noticed significant differences in the peak systolic pressure
gradients between 2ply and 4ply valves. The peak systolic pressure gradient for 2ply valves
was significantly higher (p < 0.05) as compared to the 4ply valves and closer to the
reference values [16, 17]. At heart rate of 140 bpm and stroke volume of 40 ml/beat peak
systolic pressure gradient was 137.4 ± 1.57 mmHg and at 145 bpm and 20 ml/beat it was
55.1 ± 1.4 mmHg. Both 2ply and 4ply valves had sufficient systolic pressure gradients to
keep the mitral valve closed effectively. It is possible however that the higher systolic
pressure drop across the 2-Ply PSIS valve compared to 4-ply PSIS valve may maintain
adequate valve sealing and closure while longitudinal somatic growth and remodeling
occurs.
The key factor behind the selection of these two set of parameters was considering the
closing energy losses in 4-Ply PSIS mitral valves. Energy loss was highest for 4ply PSIS
valves at heart rate of 140 bpm and stroke volume of 40 ml/beat and lowest at heart rate of
145 bpm and stroke volume of 20 ml/beat. The closing energy losses for 2ply valves were
observed to be less as compared to 4ply and bioprosthetic valves, although there was no
statistical significance in both cases (p=0.083 for HR: 140 bpm and SV: 40 ml/beat; p >
0.05). A limitation in our comparison of thinner PSIS mitral valve is the small sample size
(n = 2 valves). We believe that testing more 2ply valves will give us statistical confidence
regarding less closing energy losses in 2ply PSIS mitral valves as compared to the 4ply
PSIS valves, in a statistically significant manner. The work presented here on acute PSIS
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bioscaffold mitral valve hydrodynamic functionality results are early findings and more
valves need to be assessed to obtain a tighter data set.
With regards to 4ply PSIS valves we observed that 2ply valves performed efficiently,
however since less material is used in 2ply valves, it is important to check its structural
integrity under in vivo high press regions. The mechanical properties of these bioscaffolds
will play an important role when implanted in patients, in the way they intend to remodel
and handle stresses and strains. The collagen fibers present in cardiovascular tissues are
oriented, rendering the mechanical behavior of these tissues nonlinear and anisotropic [18].
Structural analysis of the PSIS bioscaffold showed that the fibers are aligned in a single
preferred direction along the longitudinal axis, however rarely fibers were aligned at ±30°
to the longitudinal axis [19, 20, 21]. Biaxial testing performed on these scaffolds signified
the mechanically anisotropic behavior of the material showing stiffness and strength [21,
22].
It was observed that the mechanical behavior of a single layer of PSIS material is
insufficient for most load bearing applications, however the strength of the material
increases with the increase in the number of layers or by using multiple laminations [23].
In one of the studies assessing the ball-burst strength of multilaminate PSIS scaffolds, it
was observed that increasing the PSIS layers from 2 to 4 resulted in an increase in failure
load of nearly 150%, the strength of 2ply PSIS material being 42 ± 9 N [23, 24]. In other
study using same techniques there was an increase in strength by 81 % when the number
of layers of PSIS scaffold were increased from 2 to 4 [25]. A 25.4mm smooth steel ball
was directed through the PSIS material at a constant rate of 25.4 mm/min. The mean ballburst strength of 2ply PSIS scaffold showed maximum loading of 73.67 ± 7.66 N and that
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of 4ply was 133.53 ± 21.31 N [25]. Likewise, the 2 ply materials displayed higher stresses
at equivalent strains compared to the thicker 4ply laminates. In the same study, prior to
rupture, it was noted that 2ply and 4ply materials required comparable forces to deflect to
similar indentations [25].
However, the 2ply Cormatrix PSIS material is proposed to be used in neonates, infants
and children due to its handling and remodeling characteristics [26]. The performance
assessment of these valves in the present study confirmed that the 2ply materials possesses
adequate material properties and can endure the tension, suture tension, and hemodynamic
forces exerted on the material when used for pediatric cardiovascular repair in the acute
timeframe [26].
In one of the papers, the 2ply PSIS bioscaffold was utilized for tricuspid valve
replacement in an ovine model [27]. Echocardiography results exhibited normal forward
flow with excellent coaptation of the bioscaffold leaflets from the day of implantation till
the day of explant. When explanted, the 2ply PSIS valves showed distinctive trileaflet
structure similar to native tricuspid valve. Considerable host-cell infiltration, structural
reorganization of the bioscaffold, elastin generation at the annulus was confirmed upon
histopathologic investigation by 3 months, and by 5 months’ time span, amplified collagen
organization and glycosaminoglycan presence were detected in the leaflets.
The ball-burst studies confirmed that 2ply material is weaker in comparison to the 4ply
material. However, in one of the studies following implantation as a body wall scaffold in
canine model, it was shown that approximately at day 45, after implantation, there was
increase in the strength of the bioscaffold which was greater than the native tissue [28]. For
pediatric applications, the 2ply valves are capable of enduring the hemodynamic forces and
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tensions effectively, as mentioned above. For pediatric application, the performance testing
established that 2ply material surpasses the required biomechanical properties [26]. But, if
the degradation and the remodeling of the 2ply substrates is slow, it can be a concern for
the proper functioning of the valves. Thus, it is necessary that the 2ply valves enable tissue
infiltration at a faster rate as compared to 4ply valves and that the growth is appropriate
once implanted.
Nevertheless, we need to perform extensive mechanical and fatigue testing of both 2ply
and 4ply material intended to be used as a mitral valve substitute. It is important that the
2ply PSIS material maintain its integrity during initial period under high stress
environment.
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CHAPTER 7 Conclusion and Future Direction
Our current study involving extracellular matrix PSIS bioscaffold mitral valves, has the
potential to solve the limitations related to the conventional prosthetic mitral valves. PSIS
in recent times has been reported as a candidate material for valve replacement and repair
due to its capacity to support, bioscaffold degradation and allow tissue ingrowth [1, 2]. In
this study, we describe in vitro results of acute hydrodynamic functionality of PSIS
bioscaffold assembled mitral valvular constructs compared to commercially available
trileaflet porcine bioprosthetic valves and relate findings to potential long-term
complications. This study was designed particularly for pediatric populace as the need for
alternate valve replacement substitutes providing somatic growth is more in them.
Our two aims have investigated hydrodynamic functionality and characteristics of 4ply
and 2ply PSIS bioscaffold mitral valves as compared to the porcine trileaflet bioprosthetic
control group (Edwards Lifescience). Both these approaches had robust data sets and were
physiologically similar to the control group, with some inconsistencies in the ventricular
pressure between the two group, especially during the systolic phase, as we increase the
heart rate.
The major conclusions of this study were:


PSIS bileaflet valves appear to demonstrate acute functionality for treatment of

critical mitral valve disease. The PSIS valves performed hydrodynamically similar to the
bioprosthetic valves with regards to the opening and closing functionality in short term.
This can potentially predict mid-term to long-term. However, we observed differences in
the peak systolic pressure gradients between the two groups, potentially due to the material
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properties. Nevertheless, both the valves closed effectively which is supported my minimal
RF (%).


Energy losses were not significantly different (p > 0.05) between PSIS and a

commercially available bioprosthetic valve for mitral valve pediatric application, but was
for aortic valve under adult physiological conditions [3]. For the pediatric conditions, we
observed that the percentage increase in the energy losses in the PSIS valves were similar
to that of the bioprosthetic valves when we increased the heart rate or the stroke volume.
However, doubling of cardiac output from child-to-adulthood increased the energy losses
by more than 3.5 times for both the groups, which appears to be a natural increase with
age, since this also occurred in the bioprosthetic valve control group. On the other hand,
even though the PSIS valves have the ability to grow with the patient, it needs to be
longitudinal as well as symmetric. Any abrupt changes to the growth factor may affect the
PSIS valves adversely as well as the energy loss metric which could increase rapidly, thus
overworking the heart.


2ply PSIS valves have shown early promising results by maintaining the pressure

gradient across the valves, in the clinically acceptable range [4], during the forward flow
when compared to the 4ply valves. There was increase in the forward flow in these valves
providing greater flow rate. Here we observed that the forward flow during the diastolic
phase when the mitral valve is open was significantly higher than both the 4ply PSIS valves
and Edwards Lifescience bioprosthetic valves. However, we noticed significantly higher
RF (%) (p<0.05), though clinically unremarkable [5]. Also, 2ply valves are attractive in
terms of less usage of biomaterials. This will potentially reduce demand for de nevo tissue
replacement when implanted in patients. Correspondingly, 2ply valves have the potential
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to remodel faster when compared to their thicker counterparts, provided the growth is
consistent with time and there is gradual degradation of the material along with the
symmetric growth of the native tissue.


From the literature study of ball burst strengths of 2ply and 4ply PSIS material, we

observed that the 2ply material is weak in comparison to the 4ply material. However, 2ply
PSIS valves are intended to be used in infants and small patients having low cardiac
pressure regions. Biomechanical testing and studies of the 2ply Cormatrix PSIS valves
demonstrated adequate supporting material properties like tensile strength and endurance
of hemodynamic forces exerted on the material when used in infants and children [6]. Also,
in vivo study in ovine model demonstrated excellent coaptation of the 2ply leaflets along
with proper growth.
Limitations of our study:


Our study had certain limitations. One of them was the sample size in each group.

We believe that by testing more valves we will get more robust data. Thus, we will be able
to compare each hydrodynamic parameter more effectively.


The other limitation was considering the anatomy of the mitral valve. The mitral

valve is a complex structure consisting of several components which function in harmony
with each other in order to open and close in high pressure environment, during diastolic
and systolic phase respectively [7]. Any changes in one or more of these components can
have adverse effect on the leaflet closure thus resulting in regurgitation and more energy
being lost during the systolic phase. Thus, normal mitral valve relies on each component
for the efficient hydrodynamic functionality. However, the PSIS valve design in our study
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does not reflect these complexities including the chordae tendinae and the papillary
muscles and solely focuses on the leaflets.


Also, we didn’t compare the durability (i.e., fatigue properties) of the three groups,

especially between the PSIS valves and the bioprosthetic valves. Durability is an important
component of the valve design, since these scaffolds would perform in vivo under high
pressure regions when used for valve replacement procedures. It is essential to observe the
fatigue properties of 2ply and 4ply PSIS valves to reach more effective conclusion.


Lastly, we didn’t look at the growth component of the PSIS valves when implanted

in high pressure region, in human body. Even though, remodeling of the implanted PSIS
bioscaffold by fibrosis has been documented in the literature [8], but we are still unclear
on the mechanism through which this bioscaffold degrades and permits tissue filling, and
in this case valvular matrix tissue filling to be precise s. Correspondingly we didn’t look at
the immune response of the PSIS bioscaffold valve when used as valve replacement in
vivo.
Future Directions:


Both the 2ply and 4ply valves still need to be further characterized at pediatric

conditions. Our immediate focus after this work is to test more valves; 2ply, 4ply and
bioprosthetic valves. Testing more valves will give us statistical confidence and will help
us to complete our in vitro study more effectively.


After this we will like to conduct durability test of these 2ply and 4ply valves to

show how the PSIS bioscaffold leaflets would survive hundreds of millions of cycles under
physiological pulsatile conditions. This will help us to predict the long-term consequences
of in vivo conditions on these bioscaffolds, i.e. if the valves will remain functional from a
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structural standpoint, over several years and also aid us in determining at what time point
the valves are prone to fatigue.


Our long-term goal is to see how these PSIS valves grow and its immune response

in vivo under physiologically dynamic conditions. CorMatrix PSIS material is
biodegradable and has the potential to act as a remodelling scaffold. Further investigation
is required to determine how the PSIS material is being cellularized after it is implanted
into the patient along with the rate of its degradation to warrant somatic growth. To achieve
this knowledge, in vivo evaluation in an appropriate animal model is essential. We have
proposed non-human primates for this study. Because of the anatomical and physiological
closeness to humans, we have proposed Baboons as our in vivo model. This will give us
an insight on longitudinal somatic growth, immune response, extent of PSIS
biodegradation, de novo tissue regeneration and biochemical structure and phenotype of
tissue growth. Thus, will help us interpret the long-term effectiveness of PSIS bioscaffold
valves in vivo for critical congenital heart valve defects in infants and children.
In conclusion, PSIS bi-leaflet valves appear to exhibit equivalent short term
hydrodynamic functionality to standard bioprosthetic valves in the mitral position and also
the 2ply PSIS valves have shown early promising results. Thus, on the basis of our
hydrodynamic assessment, the supporting claims of adequate biomechanical properties of
the 2ply materials for pediatric applications, the in vivo growth in ovine model and the
potential of biodegradation of the material and tissue replacement with less demand on the
human body, we can conclude that 2ply PSIS mitral valves are better when compared to
the 4ply valves when used in infants and children. Nonetheless, we need to assess how the
bioscaffold degrades and need to check if the growth is rapid, sufficient and symmetric.
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